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Abstract 
Purpose: Lung-MAP (SWOG S1400) is a master platform trial assessing targeted therapies in squamous 
non-small cell lung cancer (sqNSCLC). The objective of study C (S1400C) was to evaluate the response 
rate to palbociclib, a CDK 4/6 inhibitor, in patients with cell cycle gene abnormalities. 
Methods: Patients with sqNSCLC, Performance status (PS) 0-2, normal organ function, who had 
progressed after at least one prior platinum-based chemotherapy with CDK 4 or CCND1/2/3 
amplifications on tumor specimens were eligible. The study was originally designed as a phase II/III trial 
comparing palbociclib to docetaxel, but was modified to a single arm phase II trial with primary 
endpoint of response when immunotherapy  was approved.  If two or fewer responses were seen in 
the first 20 pts, then the study would cease enrollment. 
Results:  Eighty-eight patients (9% of patients screened) were assigned to S1400C, and 53 patients 
enrolled (including 17 to docetaxel). One patient registered to docetaxel was re-registered to receive 
palbociclib after progression on docetaxel. The frequency of cell cycle gene alterations in the eligible 
palbociclib patients (N=32) were: CCND1 (n=26, 81%), CCND2 (n=3, 9%), CCND3 (n=2, 6%), CDK4 (n=1, 
3%). Thirty-two eligible patients received palbociclib. There were two partial responses (6% RR, 95% CI: 
0%-15%), both with CCND1 amplification.  Twelve patients had stable disease (38%, 95% CI: 21%-54%).   
Median progression-free survival was 1.7 months (95% CI: 1.6-2.9 months) and median overall survival 
was 7.1 months (95% CI: 4.2-12.5).   
Conclusions: Palbociclib as monotherapy failed to demonstrate the pre-specified criteria for 
advancement to phase III testing.  
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Introduction 
Despite substantial progress in identifying targeted agents with activity in advanced non-squamous 
non-small cell lung cancer (NSCLC), there have been few advances in developing such agents in 
squamous cell NSCLC (sqNSCLC).  Several studies have identified potentially actionable mutations in 
this subset of disease.
1
  The  Lung Master Protocol (Lung-MAP, SWOG 1400) was developed with the 
goal of establishing a mechanism for genomically screening a large, homogeneous, population of 
sqNSCLC and subsequently assigning and accruing simultaneously to sub-studies evaluating agents 
targeting specific molecular abnormalities.
2
  When originally designed, biomarker-driven sub-studies in 
the protocol compared new targeted therapy or targeted therapy combinations to standard of care 
therapy (i.e., docetaxel) based on designated therapeutic biomarker-drug combinations, with the 
ultimate goal of obtaining FDA approval of new targeted therapies in this setting.  In December 2015, 
due to the rapid development and approval of immunotherapy in NSCLC, the protocol was re-designed 
to evaluate biomarker-driven therapies using a single arm screening design to be followed by 
randomized assessments if specified levels of activity were met.
3-6
  
Sub-study C (S1400C) of Lung-MAP tested the concept of targeting cyclin dependent kinase (CDK) 
abnormalities with the selective CDK4/6 inhibitor palbociclib.   Unrestricted proliferation is a hallmark 
of cancer and frequently results from abnormality in the retinoblastoma (Rb) pathway.  Rb in its active, 
unphosphorylated state, inhibits progression through the cell cycle. For the cell to enter mitosis, Rb is 
phosphorylated by the cyclin D-CDK 4/6 complex.  Inactivation of Rb, by deletion, mutation or 
increased activation of the cyclin D-CDK 4/6 complex results in unrestricted proliferation.  In sqNSCLC, 
Rb itself is rarely mutated.  However, abnormalities of CDKN2, which encodes p16 (INK4), the primary 
inhibitor of the cyclin D-CDK 4/6 complex are common, as is amplification of D-type cyclins (encoded 
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by CCND1,2,3) or CDK-4/6.  In squamous cell carcinoma, CCND1 was found to be amplified in a number 
of tumors evaluated, including sqNSCLC. The Cancer Genome Atlas (TCGA) demonstrated CCND1 
amplification in 12% of squamous cell carcinoma, although these often occur in association with other 
abnormalities of the CDK4/Rb pathway. In addition, many of these amplifications were associated with 
loss of p16, contributing to further disruption of the cyclin D-CDK4/6-Rb-p16 axis. Although Rb loss was 
detected in some of the analyzed specimens, they did not overlap with CCND1 amplifications.
1, 7
  
Palbociclib (PD0332991) is an oral, selective CDK4/6 inhibitor that has been tested in multiple phase I, 
II and III trials and  approved in combination with letrozole for advanced breast cancer.  In prior 
studies, a schedule of 3 weeks on treatment/1 week off treatment was found to be the best tolerated 
and active and was therefore chosen for this trial.
8, 9
  
Patients and Methods 
When the trial opened in June 2014, the eligibility criteria specified that patients were allowed to have 
only a single line of prior therapy for stage III or IV recurrent disease and have a performance status 
(PS) = 0-2. In April 2015, the study was amended to allow any number of lines of prior therapy for stage 
IV NSCLC or for lower stage disease within one year. In December 2015, the study was amended to 
only allow PS 0-1 and redesigned to be a single arm study.  In addition to these criteria, patients were 
required to have normal hematologic, hepatic and renal function. Patients on strong CYP3A4 inhibitors 
and/or inducers were not allowed to enroll. Due to the known cardiac effects of the drug, patients with 
a known personal or family history of long or short QT syndrome, Brugada syndrome or torsade de 
pointes were excluded.  Measurable disease (by RECIST 1.1) was required. Patients with treated brain 
metastases were allowed as long as (1) metastases had been locally treated and remained clinically 
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controlled and asymptomatic for at least 14 days following treatment, AND (2) patient had no residual 
neurological dysfunction and was off corticosteroids for at least one day prior to sub-study registration.  
Following the modification to a single arm design, patients previously registered to the docetaxel arm 
were allowed to re-register to the palbociclib arm. No patient could be enrolled at an institution prior 
to review and approval by either the local Institutional Review Board or by the National Cancer 
Institute Central IRB. Written informed consent was required from all patients prior to enrollment in 
the master protocol and a separate consent was required for the specific sub-study. 
The cell cycle gene alterations required for eligibility were amplifications of CDK4, CCND1, CCND2, or 
CCND3.  Disease characterized by substitutions or fusion alterations were not eligible.  Amplification 
was defined as > 6 estimated copies (or > 7 for triploid or >8 for tetraploid samples).  Mutational 
analysis was performed on archival formalin-fixed paraffin-embedded tumor specimens using the 
Foundation One testing platform.
10
  
Palbociclib was administered orally at a dose of 125 mg daily and taken with food.  A cycle of treatment 
was 28 days with treatment given continuously for 21 days and 7 days off treatment. Disease 
assessment occurred every six weeks, and treatment could continue until progression. Dose reductions 
and adjustments were specified in the protocol (supplemental materials) and were to be discussed 
with the study chair. 
 
Statistical Considerations 
S1400C originally was a phase II/III trial with randomization between palbociclib and docetaxel.  The 
primary endpoint of the phase II component was progression free survival (PFS) and the study included 
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co-primary endpoints, PFS and overall survival (OS), in the phase III component. In December 2015, the 
design was amended to a single arm phase II trial and the docetaxel arm permanently closed to 
accrual. Patients on the docetaxel arm were not included in the analyses presented in this paper. The 
primary objective for the modified design was to evaluate the objective response rate (ORR) 
(confirmed and unconfirmed, complete and partial) in patients treated with palbociclib with stage IV 
refractory sqNSCLC. The sample size was based on a design with 91% power to rule out an ORR of 15% 
at the 5% level, if the true rate were 35%.  The observation of 10/40 (25% ORR) would be considered 
evidence to rule out the null ORR and evidence to pursue an independent randomized phase III.  The 
design included an interim analysis at 20 patients evaluable for response and would continue accrual if 
at least three responses were observed. A key secondary objective was an investigator assessment of 
median PFS (mPFS). If the ORR rate was less than 25% but the mPFS was at least 4.5 months, this 
would be considered sufficient evidence to continue to the follow-on Phase III. With 40 patients, this 
design had 90% power to rule out a median PFS of 3 months or less, if the true mPFS was 6 months, at 
the 0.05 1-sided level. The observation of an mPFS of at least 4.5 months would be considered 
evidence to rule out a mPFS of 3 months or less. 
Binary proportions and associated 95% confidence intervals were estimated. Survival distributions 
were estimated using the method of Kaplan-Meier and the Brookmeyer-Crowley method was used to 
estimate confidence intervals.   
Results 
The study was open to accrual from June 15, 2014 to September 1, 2016.  In this time, 973 patients 
were screened for the overall study. Eighty-eight patients (9% of those screened while the study was 
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actively accruing) were assigned to S1400C.  Fifty-three patients were enrolled (including 17 to 
docetaxel before the study redesign). One patient registered to docetaxel re-registered to palbociclib 
after progression on docetaxel. The study did not meet the criterion to continue past the interim 
analysis and was closed to accrual on September 1, 2016. Of the 37 patients enrolled to the palbociclib 
arm, five were ineligible (four inadequate baseline labs, one did not progress on prior therapy).  The 
demographics for the 32 eligible and evaluable patients are shown in Table 1.  The frequency of cell 
cycle gene alterations in the eligible palbociclib patients (N=32) were as follows: CCND1 (n=26, 81%), 
CCND2 (n=3, 9%), CCND3 (n=2, 6%), CDK4 (n=1, 3%), Table 2.   
Patients received a median of two cycles (range = 1-17) of palbociclib.  The AEs were as expected for 
palbociclib (Table 3).  Three patients discontinued therapy due to AEs.    Five patients experienced 
Grade 4 AEs including lymphopenia (3), neoplasms (1) and thrombocytopenia (1).  Thirteen others 
experienced Grade 3 treatment-related AEs. 
There were two confirmed partial responses observed for a response rate of 6% (95% CI: 0%-15%).  A 
waterfall plot depicting tumor response is presented in Figure 1. Twelve patients demonstrated stable 
disease (38%, 95% CI: 21%-54%) for a disease control rate of 44% (95% CI: 27%-61%), response was not 
assessable in one patient, and one patient had symptomatic deterioration as their best objective 
response with no follow-up tumor measurements.  The median progression free survival was 
1.7 months (95% CI: 1.6-2.9) and overall survival was 7.1 months (95% CI: 4.2-12.5) (Figure 2).  The 
one- and two-year estimates of survival are 37.5% and 12.1%, respectively. Of the two partial responses, 
one has progressed (duration of response, 7.7 months), and one died without evidence of progression 
(duration of response 12 months).  Of note, both of these patients demonstrating partial response had 
CCND1 amplification.   
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Discussion 
Palbociclib did not demonstrate antitumor activity in this genomically selected patient population with 
sqNSCLC.  In contrast, well-differentiated or dedifferentiated liposarcoma (WDLD/DDLS) is the 
paradigm malignancy characterized by CDK4 amplification and palbociclib has demonstrated growth 
inhibition in WDLS/DDLS cells in vitro and in xenograft models. Proof of principle that targeting CDK4 
amplified cancer with palbociclib can be therapeutically important was established in a phase II trial of 
palbociclib in WDLD/DDLS.  In 60 evaluable patients, the 12-week PFS was 57.2% and median PFS 17.9 
weeks.  One patient had a complete response.
11
  
Despite this proof of principle demonstration that CDK/cyclin abnormalities might predict for benefit of 
this type of agent, it is not clear that such abnormalities are necessary for activity. All three currently 
approved CDK 4/6 inhibitors (palbociclib, abemaciclib, ribociclib) have primarily demonstrated benefit 
in hormone responsive breast cancer when combined with anti-estrogens or other hormonally active 
agents regardless of demonstration of genetic abnormalities.
12
  Abemaciclib has demonstrated single 
agent activity in hormone receptor positive breast cancer as well.
13
 This likely occurs because the 
CDK4/6-cyclin D1 complex is a direct target of estrogen receptor signaling.
14
    
It is possible that the wrong subgroup of lung cancer patients was targeted in this trial. Preclinical and 
early clinical evidence demonstrates that the CDK4/6 inhibitor abemaciclib is particularly active in KRAS 
mutant lung cancers. These are almost exclusively seen in non-squamous carcinoma.
15
  A study 
evaluating abemaciclib versus erlotinib in the second line treatment of NSCLC with K-Ras mutations 
(and therefore likely adenocarcinoma) was negative for the primary endpoint of OS, however 
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demonstrated superior PFS (3.6 months vs. 1.9 months, p <.001) and higher response rate (8.9% vs. 
2.7%, p =.01).
15 
An additional issue is that the postulated mechanism of action for CDK/cyclin agents, inhibition of 
progression through the cell cycle, is hypothetically more likely to demonstrate cytostatic activity and 
stable disease as opposed to cytocidal activity and tumor response.  For this reason, the secondary 
endpoint of mPFS was incorporated into the trial. Unfortunately, this was also negative.  
Despite the results of this study, there was some evidence of activity with two partial responses.  It 
should be noted that palbociclib has demonstrated little activity as a single agent in breast cancer, but 
is clearly beneficial when combined with other agents.
12
   Additionally, evidence from other trials that 
indicates that additional evaluation of this pathway, possibly in combination with other agents, may 
still be beneficial in some patients with sqNSCLC.  
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Tables and Figures 
 
Table 1: Patient Demographics and Characteristics 
 N (%) 
(N = 32) 
Age Median (range) 67.3 (53-80.7) 
Male Gender 21 (66%) 
Performance status  
0 
1 
2 
 
13 (41%) 
18 (56%) 
1 (3%) 
Race/Ethnicity 
White 
Black 
Asian 
Hispanic 
 
28 (88%) 
3 (9%) 
1 (3%) 
0 (0%) 
Number of Prior Lines of 
Therapy for Stage IV Disease  
0 
1 
2 or more  
 
 
8 (25%)* 
23 (72%) 
1 (3%) 
Smoking Status 
Current Smoker 
Former Smoker 
Never Smoker 
 
13 (41%) 
18 (56%) 
1 (3%) 
Brain Metastases 
Present 
Absent                                                                         
2(6%) 
30 (94%) 
 
 
 
* per protocol, patients were eligible if they received chemotherapy in the adjuvant or as part of combined modality 
therapy within one year of enrollment. 
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Table 2: Gene Alterations Detected on FMI NGS Screening 
 Palbociclib 
(n=32) 
CCGA Study Gene Alterations  
     CCND1 26(81%) 
     CCND2 3(9%) 
     CCND3 2(6%) 
     CDK4 1(3%) 
  
Number of CCGA Study Gene Alterations  
     1 32(100%) 
  
  
Other Concomitant Gene Alterations  
Short Variants  
     TP53 30(94%) 
     CDKN2A, MLL2 8(25%) 
     NFE2L2 6(19%) 
     PTEN 4(13%) 
     ARID1A, LRP1B, PIK3CA 3(9%) 
     APC, BAP1, KRAS 2(6%) 
     ATRX, BRCA2, BRIP1,  
     CREBBP, DAXX, DNMT3A,  
     EZH2, FANCA, FBXW7, FLT4,  
     GRIN2A, IGF1, IKZF1, KLHL6,  
     MET, NCOR1, NF1, NF2,  
     NOTCH1, NOTCH3, NOTCH4,  
     SF3B1, STAT4, STK11, TET2,  
     TRRAP, TSC2, WT1 
1(3%) 
Copy Number Alterations  
     FGF19, FGF3, FGF4 24(75%) 
     SOX2 16(50%) 
     PIK3CA 11(34%) 
     CDKN2A 10(31%) 
     CDKN2B 9(28%) 
     FGF12, MYC 6(19%) 
     KRAS 5(16%) 
     EPHB1, FGFR1, MYST3, REL,  
     ZNF703 
3(9%) 
     AKT2, EGFR, EMSY, ERBB2,  
     FGF23, FGF6, JAK2, KDM5A,  
2(6%) 
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     KDR, PTEN 
     AKT3, BCL2L2, CCNE1, CDK4,  
     IGF1R, IKBKE, KDM6A, KIT,  
     LRP1B, MDM2, MDM4,  
     NFKBIA, NKX2-1, RICTOR,  
     STK11, TP53 
1(3%) 
Rearrangements  
     LRP1B 3(9%) 
     ABL1, MLH1, MLL2, PIK3R2 1(3%) 
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Table 3: Adverse Events Attributed to Treatment 
Adverse event Grade of AE 
N = 32 
 
3 4 5 
AST increased 1(3%)   
Anemia 4(13%)   
Anorexia 1(3%)   
Chronic Kidney Disease 1(3%)   
Dyspnea 1(3%)   
Fatigue 5(16%)   
Generalized muscle weakness 1(3%)   
Hyperglycemia 2(6%)   
Hyponatremia 1(3%)   
Hypotension 1(3%)   
Lung infection 1(3%)   
Lymphopenia 6(19%) 3(9%)  
Neoplasms, all  1(3%)  
Neutropenia 5(16%) 
 
 
Thrombocytopenia 1(3%) 1(3%)  
Leucopenia 6(19%) 
 
 
Maximum grade of any AE 13(41%) 5(16%) 0 
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Figure 1. Waterfall plot of response to palbociclib 
 
  
 
 
Each vertical bar represents a patient’s best percent decrease in tumor burden when compared to 
baseline as defined by RECIST 1.1. Only patients with measurable disease at baseline are presented in 
the plot. Patients who did not have follow up tumor disease assessment are presented at the very left 
of the plot marked with ‘**’. Patients who had new lesions appear at their first follow-up assessment 
or who expired prior to the first scheduled the disease assessment and the death can reasonably be 
assumed to be due to disease progression are represented graphically as a 100% increase in tumor 
burden. Patients who had symptomatic deterioration at first disease assessment are coded as 
“Symptomatic deterioration”. Negative numbers represent decrease in tumor burden from baseline 
while positive numbers represent increase in tumor burden from baseline.  
+ this patient had complete disappearance of disease and would have been considered a CR, however, 
the patient’s non-target brain lesion was removed surgically and per RECIST 1.1 guidelines is coded as 
having a partial response. 
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Figure 2: Progression-free Survival and Overall Survival 
 
2a: Progression-Free Survival 
 
 
 
2b: Overall Survival  
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